A global endocrine condition marked by high blood sugar
A government-commissioned review has found that care leavers aged 18-24 die at three to four times the rate of their peers, with 18-year-olds facing a cliff in support. The report calls for a national overhaul of housing, personal advisers and mental health support as ministers pledge a £25m commitment to connected housing.
Doctors and detainees in Gaza faces harsh detention under Israeli law, with 14 Gazan doctors and 1,300 Palestinians detained without charge. Reports highlight torture, starvation and restricted medical access, drawing international condemnation and calls for release.
England’s children’s mental health referrals have surpassed 1 million for 2024-25, a rise driven by anxiety and suspected autism. Wait times remain long, with more than 60,000 waiting over two years. The report calls for joined-up services across health, education and social care to meet demand.
Nice has issued a draft guideline for PMOS that mandates annual checks, earlier diagnosis, and monitoring of long-term risks. It renames the condition from PCOS to PMOS to reflect broader health impacts. It also rules out laser hair removal as a cost-ineffective treatment, instead urging contraception-based management and IVF options where appropriate.
The 340B program, which lets hospitals buy discounted outpatient drugs for low-income patients, is facing a new CMS rule changing reimbursement formulas to reduce payments by about 40%. The move aims to lower patient costs but could shrink hospital revenues and affect services and jobs. The rule follows an executive order in 2025 and reflects ongoing political battles between hospitals and the pharmaceutical industry.
A Brazilian study links high intake of artificial sweeteners to faster cognitive decline over eight years, especially among those under 60. The study analyzed seven sweeteners and tracked nearly 13,000 participants, finding the highest-intake group aged 52 showed a 62% faster decline in mental performance versus the lowest intake group.
Novo Nordisk has filed a US lawsuit accusing Eli Lilly of false advertising over weight‑loss and diabetes drugs, arguing Lilly used outdated trial data to claim superiority. Lilly defends its campaigns, citing SURMOUNT‑5 results. The case centers on GLP-1 treatments and the race for market dominance, with potential damages and corrective advertising at stake.
Federal SNAP reform has tightened eligibility and shifted costs to states, triggering a sharp drop in participation and putting pressure on food banks. Arizona records the largest decline, with state processes becoming more burdensome and delivery times longer as programs adjust. Projections warn of continued reductions without congressional action.
A Taiwan study finds that when one spouse develops dementia, the other is more likely to receive the same diagnosis. Relative risk is 74% higher for women and 69% for men, with five-year absolute risks of 6.5% and 9.2% respectively.
Recent reporting shows chronic inflammation is linked to aging disorders such as cancer and Alzheimer’s. Studies indicate inflammation may be a cause, not just a symptom, of broad health risks. Policy and lifestyle factors are under scrutiny as researchers push for preventative strategies.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
Starbucks and Bank of America are recalibrating GLP-1 weight-loss drug coverage amid rising costs. Starbucks will exclude GLP-1s for weight loss from October for benefits-eligible employees; Bank of America says its GLP-1 program costs exceed $250 million annually and accounts for about 13% of healthcare spend. Other firms weigh limits as utilization climbs.
The NHS has been forced to confront ongoing summer pressures as heatwaves drive higher A&E attendances, equipment failures, and drought-related health risks. Officials say planning for summer pressures is now essential, with public awareness campaigns and infrastructure upgrades in focus.
Employers increasingly monitor workers using digital tools first deployed during the pandemic. A wave of tracking spans location, productivity, communications, and device access, creating detailed dossiers that can punish or predict behavior. Pharmacist Lannie Duong’s case illustrates how hours, calls, and appointments are quantified, fueling burnout and union organizing.